ALLO-605 is under clinical development by Allogene Therapeutics and currently in Phase II for Refractory Multiple Myeloma. According to GlobalData, Phase II drugs for Refractory Multiple Myeloma have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ALLO-605’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ALLO-605 is under development for the treatment of relapsed/refractory multiple myeloma. The therapeutic candidate is a retroviral vector consists of allogeneic, turbo charged T cells modified to express chimeric antigen receptor (CAR) acts by targeting BCMA. The therapeutic candidate is developed based on AlloCAR T platform and off-the-shelf enhanced by TALEN gene editing technology. It is administered through parenteral route.
Allogene Therapeutics overview
Allogene Therapeutics is a clinical stage biotechnology company that develops allogeneic T-cell (CAR T) therapies for cancer. The company’s pipeline product includes UCART19, ALLO-501, ALL0-501A, ALL0-316, ALL0-819, ALL0-605 and ALL0-715. Its ALL0-501 and ALL0-501A an off-the shelf allogeneic CAR T therapy candidate for the treatment of hematological malignancies, CD70 and DLL3 for solid tumors and ALLO-647, an anti-CD52 monoclonal antibody used as lymphodepleting agent. Allogene Therapeutics develops products in the therapeutic areas of cancers and solid tumors. The company seeks to partner with other companies in the research and development of immuno-oncology therapies. Allogene Therapeutics is headquartered in South San Francisco, California, the US.
For a complete picture of ALLO-605’s drug-specific PTSR and LoA scores, buy the report here.